Clinical Trials Sponsored by Akebia Therapeutics Inc.

Total 2977 results

Akebia Therapeutics

Completed

Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects

Anemia Associated With Chronic Kidney Disease (CKD)

United States
Akebia Therapeutics

Suspended

Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents (CORRECTION)

Anemia of Chronic Kidney Disease

United States
Akebia Therapeutics

Completed

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Anemia | Dialysis-Dependent Chronic Kidney Disease

United States, Italy, Korea, Republic of, Portugal, Russian Federation, Ukraine, Poland, Argentina, Brazil, Germany, Mexico
Akebia Therapeutics

Completed

16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis

Anemia | End Stage Renal Disease

United States
Akebia Therapeutics

Completed

Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4

Chronic Kidney Disease

United States
Akebia Therapeutics

Terminated

Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents

Anemia | Dialysis-Dependent Chronic Kidney Disease

United States
Akebia Therapeutics

Completed

A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function

Hepatic Impairment

United States
Akebia Therapeutics

Completed

Drug-Drug Interaction Study of Vadadustat With Cyclosporine, Probenecid and Rifampin

Drug Interaction Potentiation

Canada
Akebia Therapeutics

Completed

A Study in Evaluating Bioequivalence of Test and Reference Vadadustat 450 MG and 150 MG Tablets and to Determine Food Effect on the 450 MG Tablet

Healthy

United States
Akebia Therapeutics

Completed

Study to Evaluate the Effect of Rabeprazole on the Pharmacokinetics of Vadadustat

Pharmacokinetics | Drug Interaction Potentiation

Canada
Akebia Therapeutics

Completed

Relative Bioavailability of Two Formulations of AKB-6548 and the Food Effect of a New Tablet in Healthy Adult Subjects

Healthy

United States
Akebia Therapeutics

Withdrawn

Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) (TRILOGY)

Anemia | Dialysis-Dependent Chronic Kidney Disease

United States
Akebia Therapeutics

Completed

Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa (FO2RWARD-2)

Anemia | Dialysis-dependent Chronic Kidney Disease

United States
Akebia Therapeutics

Completed

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Anemia | Dialysis-Dependent Chronic Kidney Disease

United States, Italy, Canada, Korea, Republic of, United Kingdom, Australia, Germany, Israel, France, Portugal, Bulgaria, Russian Federation, Ukraine, Poland, Brazil, Argentina, Mexico, Serbia
Akebia Therapeutics

Completed

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Anemia | Non-Dialysis-Dependent Chronic Kidney Disease

United States, Italy, Spain, Czechia, Korea, Republic of, Malaysia, Australia, New Zealand, United Kingdom, Germany, Turkey, Ukraine, France, Hungary, Austria, Israel, Bulgaria, Russian Federation, Romania, Slovakia, South Africa, Canad... and more
Akebia Therapeutics

Completed

Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

Anemia | Dialysis Dependent Chronic Kidney Disease

Japan
Akebia Therapeutics

Completed

A Study in Evaluating Bioequivalence Between Test and Reference Formulations of Vadadustat Tablets in Healthy Adults

Healthy

United States
Akebia Therapeutics

Completed

Drug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and Furosemide

Drug Interaction Potentiation

Canada
Akebia Therapeutics

Suspended

Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease (CONVERSION)

Anemia of Chronic Kidney Disease

United States
Akebia Therapeutics

Completed

20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

Anemia | Chronic Kidney Disease

United States
Akebia Therapeutics

Completed

42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

Anemia | Kidney Disease

United States
Akebia Therapeutics

Completed

Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia

Anemia | Kidney Disease

United States
Akebia Therapeutics

Completed

Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease

Anemia | Non-Dialysis-Dependent Chronic Kidney Disease

United States, Italy, Korea, Republic of, Australia, New Zealand, South Africa, United Kingdom, Spain, Ukraine, Hungary, Israel, Bulgaria, Russian Federation, Mexico, Poland, Brazil, Argentina, Malaysia, Puerto Rico, France
Akebia Therapeutics

Completed

Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)

Anemia | Non-dialysis Dependent Chronic Kidney Disease

Japan
Akebia Therapeutics

Completed

Study in Healthy Adult Subjects to Assess the Effect of Phosphate Binders on the Pharmacokinetics of a Single Dose of Vadadustat

Healthy Volunteers

Canada
Akebia Therapeutics

Completed

Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease

Anemia Associated With Chronic Kidney Disease

United States
Akebia Therapeutics

Completed

Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and Simvastatin

Drug Interaction Potentiation

Canada
Akebia Therapeutics

Completed

Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers

Healthy Volunteers

United States
Akebia Therapeutics

Completed

Effects of Ferrous Sulfate on the Pharmacokinetics of AKB-6548

Healthy Volunteers

United States
Akebia Therapeutics

Completed

Effect of AKB-6548 on the Pharmacokinetics of Celecoxib

Healthy Volunteers
Akebia Therapeutics
Cyclerion Therapeutics

Completed

A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria

Type 2 Diabetes Mellitus With Diabetic Nephropathy

United States
Akebia Therapeutics
Cyclerion Therapeutics

Completed

A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF) (CAPACITY-HFpEF)

Heart Failure With Preserved Ejection Fraction

United States, Canada
USRC Kidney Research
Akebia Therapeutics Inc.

Completed

Auryxia (Ferric Citrate) Therapy for In-Center and Home Dialysis Participants (IMPACT)

Renal Insufficiency | Hyperphosphatemia | Anemia, Iron Deficiency

United States
Akebia Therapeutics
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)

Anemia

United States, Italy, Spain, Hungary, Czechia, Poland
USRC Kidney Research
Akebia Therapeutics

Active, not recruiting

Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease (FRONTIER)

Disease Progression | Renal Insufficiency, Chronic | Hyperphosphatemia | Anemia, Iron Deficiency | Renal Anemia | Iron | Cardiovascular

United States
Kemia, Inc

Completed

Use of KC706 for the Treatment of Pemphigus Vulgaris

Pemphigus Vulgaris

United States
Akela Pharma, Inc.

Unknown

Safety of Fentanyl TAIFUN Treatment (FINDS)

Breakthrough Cancer Pain

Poland
BlackThorn Therapeutics, Inc.
Neumora Therapeutics, Inc.

Completed

Study in Major Depressive Disorder With BTRX-335140 (NMRA-335140) vs Placebo

Major Depressive Disorder

United States
Sirion Therapeutics, Inc.
ReVision Therapeutics, Inc.

Completed

Study of Fenretinide in the Treatment of Geographic Atrophy Associated With Dry Age-Related Macular Degeneration

Geographic Atrophy | Dry Age Related Macular Degeneration
The University of Texas Health Science Center,...
United States Department of Defense; Akebia Therapeutics Inc.

Completed

Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)

Coronavirus Infection | Acute Respiratory Distress Syndrome

United States
Therapeutics, Inc.

Completed

Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis (307)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 310)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis

Psoriasis | Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison Study of UHE-103 Cream in Subjects With Moccasin Type Tinea Pedis

Tinea Pedis

United States, Puerto Rico
Therapeutics, Inc.

Completed

A Safety Study of 188-0551 Spray Versus Reference Listed Drug (RLD) in Adult Subjects With Plaque Psoriasis

Plaque Psoriasis

United States, Georgia, Ukraine
Therapeutics, Inc.

Completed

A Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis (305)

Plaque Psoriasis

United States
Therapeutics, Inc.

Completed

A Comparison of 188-0551 Solution Versus Vehicle Solution in Subjects With Plaque Psoriasis (Study 203)

Plaque Psoriasis

United States

3

Subscribe